SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    D. Simon, S. Radonjic-Hösli, A. Straumann, S. Yousefi, H.-U. Simon, Active eosinophilic esophagitis is characterized by epithelial barrier defects and eosinophil extracellular trap formation, Allergy, 2015, 70, 4
  2. 2
    Sandeep K. Gupta, Joanne M. Vitanza, Margaret H. Collins, Efficacy and Safety of Oral Budesonide Suspension in Pediatric Patients With Eosinophilic Esophagitis, Clinical Gastroenterology and Hepatology, 2015, 13, 1, 66

    CrossRef

  3. 3
    Prerna Trivedy, Jonathan E. Teitelbaum, Eosinophilic Esophagitis in Children, Pediatric Drugs, 2015,

    CrossRef

  4. 4
    Hamish Philpott, Sanjay Nandurkar, Francis Thien, Peter R. Gibson, Simon G. Royce, Eosinophilic esophagitis: A clinicopathological review, Pharmacology & Therapeutics, 2015, 146, 12

    CrossRef

  5. 5
    Marc E. Rothenberg, Ting Wen, Allison Greenberg, Oral Alpan, Benjamin Enav, Ikuo Hirano, Kari Nadeau, Sergio Kaiser, Thomas Peters, Antonio Perez, Ieuan Jones, Jonathan P. Arm, Robert M. Strieter, Ronald Sabo, Kulasiri A. Gunawardena, Intravenous anti–IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis, Journal of Allergy and Clinical Immunology, 2015, 135, 2, 500

    CrossRef

  6. 6
    Susanne Radonjic-Hoesli, Peter Valent, Amy D. Klion, Michael E. Wechsler, Hans-Uwe Simon, Novel Targeted Therapies for Eosinophil-Associated Diseases and Allergy, Annual Review of Pharmacology and Toxicology, 2015, 55, 1, 633

    CrossRef

  7. 7
    Javier Molina-Infante, Alfredo J. Lucendo, Proton Pump Inhibitor Therapy in Eosinophilic Esophagitis: Current Role and Future Perspectives, Current Treatment Options in Allergy, 2015,

    CrossRef

  8. 8
    Giovanni B Pajno, Kari C Nadeau, Giovanni Passalacqua, Lucia Caminiti, Ben Hobson, David C Jay, Stefania Arasi, Fernanda Chiera, Giuseppina Salzano, The evolution of allergen and non-specific immunotherapy: past achievements, current applications and future outlook, Expert Review of Clinical Immunology, 2015, 11, 1, 141

    CrossRef

  9. 9
    Edaire Cheng, Translating New Developments in Eosinophilic Esophagitis Pathogenesis into Clinical Practice, Current Treatment Options in Gastroenterology, 2015, 13, 1, 30

    CrossRef

  10. 10
    Calman Prussin, Mucosal Immunology, 2015,

    CrossRef

  11. 11
    Joshua B. Wechsler, Paul J. Bryce, Allergic Mechanisms in Eosinophilic Esophagitis, Gastroenterology Clinics of North America, 2014, 43, 2, 281

    CrossRef

  12. 12
    Jeffrey B. Bice, Evelyn Leechawengwongs, Anthony Montanaro, Biologic targeted therapy in allergic asthma, Annals of Allergy, Asthma & Immunology, 2014, 112, 2, 108

    CrossRef

  13. 13
    Panida Sriaroon, Mark Ballow, Biological Modulators in Eosinophilic Diseases, Clinical Reviews in Allergy & Immunology, 2014,

    CrossRef

  14. 14
    Alfredo J Lucendo, Cellular and molecular immunological mechanisms in eosinophilic esophagitis: an updated overview of their clinical implications, Expert Review of Gastroenterology & Hepatology, 2014, 8, 6, 669

    CrossRef

  15. 15
    Ikuo Hirano, Seema S. Aceves, Clinical Implications and Pathogenesis of Esophageal Remodeling in Eosinophilic Esophagitis, Gastroenterology Clinics of North America, 2014, 43, 2, 297

    CrossRef

  16. 16
    Alfredo J. Lucendo, Javier Molina-Infante, Emerging Therapeutic Strategies for Eosinophilic Esophagitis, Current Treatment Options in Gastroenterology, 2014, 12, 1, 1

    CrossRef

  17. 17
    Alex Straumann, Eosinophilic Esophagitis, Gastroenterology Clinics of North America, 2014, 43, 2, 385

    CrossRef

  18. 18
    Stephen E. Attwood, Glenn T. Furuta, Eosinophilic Esophagitis, Gastroenterology Clinics of North America, 2014, 43, 2, 185

    CrossRef

  19. 19
    Alain M. Schoepfer, Ikuo Hirano, David A. Katzka, Eosinophilic Esophagitis, Gastroenterology Clinics of North America, 2014, 43, 2, 329

    CrossRef

  20. 20
    J. Bystrom, N. R. O'Shea, Eosinophilic oesophagitis: clinical presentation and pathogenesis, Postgraduate Medical Journal, 2014, 90, 1063, 282

    CrossRef

  21. 21
    Nadine Anna Caterina Landolina, Francesca Levi-Schaffer, Eosinophils as a pharmacological target for the treatment of allergic diseases, Current Opinion in Pharmacology, 2014, 17, 71

    CrossRef

  22. 22
    Antonella Cianferoni, Jonathan M Spergel, Immunotherapeutic approaches for the treatment of eosinophilic esophagitis, Immunotherapy, 2014, 6, 3, 321

    CrossRef

  23. 23
    Ilkka T. Harvima, Francesca Levi-Schaffer, Petr Draber, Sheli Friedman, Iva Polakovicova, Bernhard F. Gibbs, Ulrich Blank, Gunnar Nilsson, Marcus Maurer, Molecular targets on mast cells and basophils for novel therapies, Journal of Allergy and Clinical Immunology, 2014, 134, 3, 530

    CrossRef

  24. You have free access to this content24
    J. Molina-Infante, M. D. Rivas, M. Hernandez-Alonso, G. Vinagre-Rodríguez, J. M. Mateos-Rodríguez, C. Dueñas-Sadornil, B. Perez-Gallardo, L. Ferrando-Lamana, N. Fernandez-Gonzalez, R. Bañares, J. Zamorano, Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression, Alimentary Pharmacology & Therapeutics, 2014, 40, 8
  25. 25
    J. Epstein, J. O. Warner, Recent advances in the pathophysiology and management of eosinophilic oesophagitis, Clinical & Experimental Allergy, 2014, 44, 6
  26. 26
    Z. Diamant, P. N. Sidharta, D. Singh, B. J. O'Connor, R. Zuiker, B. R. Leaker, M. Silkey, J. Dingemanse, Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics, Clinical & Experimental Allergy, 2014, 44, 8
  27. 27
    Patricia N. Sidharta, Zuzana Diamant, Jasper Dingemanse, Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects, Fundamental & Clinical Pharmacology, 2014, 28, 6
  28. 28
    D. Simon, C. Aeberhard, Y. Erdemoglu, H.-U. Simon, Th17 cells and tissue remodeling in atopic and contact dermatitis, Allergy, 2014, 69, 1
  29. 29
    Peter Norman, Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs, Expert Opinion on Investigational Drugs, 2014, 23, 1, 55

    CrossRef

  30. 30
    Hans-Uwe Simon, Allergic inflammation: focus on eosinophils, Allergy, 2013, 68, 7
  31. 31
    Emily Kern, Ikuo Hirano, Emerging drugs for eosinophilic esophagitis, Expert Opinion on Emerging Drugs, 2013, 18, 3, 353

    CrossRef

  32. 32
    Laura B. Fanning, Joshua A. Boyce, Lipid mediators and allergic diseases, Annals of Allergy, Asthma & Immunology, 2013, 111, 3, 155

    CrossRef

  33. 33
    S. von Gunten, F. Cortinas-Elizondo, M. Kollarik, C. Beisswenger, P. M. Lepper, Mechanisms and potential therapeutic targets in allergic inflammation: recent insights, Allergy, 2013, 68, 12
  34. 34
    Evan S. Dellon, The Pathogenesis of Eosinophilic Esophagitis: Beyond the Eosinophil, Digestive Diseases and Sciences, 2013, 58, 6, 1445

    CrossRef